シプロフロキサシン

Fluoroquinolone with bactericidal effect by inhibition of bacterial DNA synthesis. Oral administration twice a daily.

It is excreted in tiny amounts into breast milk ^{(Gardner 1992, Cover 1990, Giamarellou 1989)}, much lower than the dose used to treat newborns or infants ^{(van Wattum 2019, van den Oever 1998)}. No problems attributable to ciprofloxacin have been observed in infants whose mothers took it ^{(Drobac 2005, Gardner 1992)}. The plasma levels of these infants were undetectable or very low ^{(Gardner 1992)}.

In the case of breastfeeding mothers with renal insufficiency, the levels of ciprofloxacin excreted in breast milk may be higher, reaching a relative dose (RD) of 6.3% ^{(Cover 1990)}, although this is still much lower than the dose used in the neonatal or infant period (pediatric RD of 2.6%).

Quinolone-related medication has been used in neonates and infants without known side effects ^{(Newby 2017, Dutta 2006, Belet 2004, Drossou 2004, Chin 2001, van den Oever 1998, Gürpinar 1997)}. Quinolone-related medication is excreted in tiny amounts into breast milk and absorption through the child’s gut may be interfered by calcium in the milk.^{(Fleiss 1992, Neuvonen 1991)}

A single case of pseudoembranous colitis has been published in a two-month-old infant whose mother was taking ciprofloxacin ^{(Harmon 1992)}, but both he had suffered a necrotizing enterocolitis with prolonged hospitalization in the neonatal period, and we do not know the dose took the mother, are confounding factors. ^{(Briggs 2017)}

Should it be prescribed to a nursing mother Norfloxacine, Ofloxacine and Ciprofloxacine are to be chosen since they have shown a lowest excretion into the milk. ^{(Butler 2014)}

Several authors and medical associations in the most recent consensus documents consider it compatible with breastfeeding, recommending that long-term treatments be avoided. ^{(Mahadevan 2025, Hoxsa 2025, Vauzelle 2022, McConnell 2016, Kaplan 2015, Butler 2014, Chen 2010, Spencer 2008, Nahum 2006, Bar-Oz 2003, Chin 2001)}

American Academy of Pediatrics: medication usually compatible with breastfeeding. ^{(AAP 2001)}

There is no good quality scientific evidence to support the use of ciprofloxacin as the treatment of choice for mastitis. Unreasonably prolonged or repetitive use of antibiotics is harmful to health.

Due to the publication of reports of serious or potentially serious side effects in patients treated with fluoroquinolones, several health authorities propose restricting their indiscriminate outpatient use and reserving them for certain serious diseases. ^{(EMA 2018, FDA 2016)}

See below the information of these related products:

• Ciprofloxacin Otologic Use (Safe product and/or breastfeeding is the best option.)
• Ciprofloxacin, Ophthalmic use (Safe product and/or breastfeeding is the best option.)